A previous report on 814 patients who were coronavirus disease 2019 (COVID-19) positive provided preliminary therapeutic efficacy evidence with interferon-α2b (IFN-α2b) in Cuba, from March 11 to April 14, 2020. This study re-evaluates the effectiveness of IFN-α2b during the period from March 11 to June 17, 2020. Patients received a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular or subcutaneous administration of IFN-α2b. The primary endpoint was the proportion of patients discharged from the hospital; the secondary endpoint was the case fatality rate, and several outcomes related to time variables were also evaluated. From March 11 to June 17, 2,295 patients had been confirmed to be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive in Cuba, 2,165 were treated with Heberon^® Alpha R, and 130 received the approved protocol without IFN. The proportion of fully recovered patients was higher in the IFN-treated compared with the non-IFN-treated group. Prior IFN treatment decreases the likelihood of intensive care and increases the survival after severe or critical diseases. Benefits of IFN were significantly supported by time variables analyzed. This second report confirmed our preliminary evidence about the therapeutic effectiveness of IFN-α2b in SARS-CoV-2 infection and postulated Heberon Alpha R as the main component within antiviral drugs used in the Cuban protocol COVID-19.

中文翻译：

---

干扰素α2b治疗对COVID-19患者康复的治疗效果

先前有关814例2019年冠状病毒病（COVID-19）阳性患者的报告提供了2020年3月11日至4月14日在古巴使用干扰素-α2b（IFN-α2b）的初步疗效证据。该研究重新评估了有效性在2020年3月11日至6月17日这段时间内，患者接受了口服抗病毒药（洛匹那韦/利托那韦和氯喹）的联合治疗，同时肌注或皮下注射了IFN-α2b。主要终点是出院患者的比例；次要终点是病死率，并且还评估了一些与时间变量有关的结果。从3月11日至6月17日，在古巴已确认2295例严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）阳性，其中2165例接受了Heberon治疗^®阿尔法R，和130接收到的批准的协议，而不IFN。与未用IFN治疗的组相比，用IFN治疗的患者中完全康复的患者比例更高。先前的IFN治疗会降低重症监护的可能性，并增加严重或严重疾病后的生存率。分析的时间变量显着支持了IFN的益处。这第二份报告证实了我们有关IFN-α2b在SARS-CoV-2感染中的治疗效果的初步证据，并假定Heberon Alpha R是古巴议定书COVID-19中使用的抗病毒药物的主要成分。